Paratek Pharmaceuticals, Inc. (PRTK)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.9300 |
| Open | 1.9200 |
| Bid | 1.9000 x 900 |
| Ask | 2.2600 x 800 |
| Day's Range | 1.8900 - 1.9800 |
| 52 Week Range | 1.6000 - 7.0200 |
| Volume | |
| Avg. Volume | 712,842 |
| Market Cap | 106.778M |
| Beta (5Y Monthly) | 1.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1780 |
| Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Oct 31, 2014 |
| 1y Target Est | 18.50 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for PRTK
Related Research
- Paratek Pharmaceuticals, Inc.Technical Assessment: Bearish in the Intermediate-TermMonday provided a much-needed rest for the stock market after a very large rebound last week. Following that strong week (and we've seen this before during the current decline), the "bottom-callers" are out, but not in big numbers. That's probably a good thing, as others are calling this another bear-market rally. From a technical perspective and using our own interpretation, it is far too early to call the bottom as there is just not enough of the needed evidence.RatingFair ValueEconomic Moat6 days agoArgus Research
- GlobeNewswire
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BOSTON, July 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on June 30, 2022, the Company granted stock options and restricted stock units to thirty-three new employees of the Company. These awards were granted pursuant t
- GlobeNewswire
Paratek Pharmaceuticals’ NUZYRA® Receives FDA Fast Track Designation for the Treatment of Pulmonary Nontuberculous Mycobacterial (NTM) Disease Caused by Mycobacterium Avium Complex (MAC) and Mycobacterium Abscessus (MAB)
-- Phase 2b Study in MAB Pulmonary Infections Ongoing and Enrolling as Planned -- Nonclinical Studies in MAC Initiating BOSTON, June 21, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced the U.S. Food and Drug Administration has granted Fast Track designation for the oral and IV formulations of the company’s novel, broad-spectrum antibiotic NUZYRA® (omadacycline) for the treatment of pulmonary Nontuberculous Mycobacterial (NTM) disease caused by both Mycobacte
- Simply Wall St.
Even after rising 25% this past week, Paratek Pharmaceuticals (NASDAQ:PRTK) shareholders are still down 89% over the past five years
It's nice to see the Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ) share price up 25% in a week. But that doesn't...
